Premium
Cephalosporins in Cutaneous Infections
Author(s) -
Parish Lawrence Charles,
Witkowski Joseph A.,
Snow Rodney,
Eron Lawrence,
Mogabgab William J.
Publication year - 1986
Publication title -
international journal of dermatology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.677
H-Index - 93
eISSN - 1365-4632
pISSN - 0011-9059
DOI - 10.1111/j.1365-4362.1986.tb02239.x
Subject(s) - medicine , superinfection , pseudomonas aeruginosa , proteus mirabilis , cephalosporin , staphylococcus aureus , ceftazidime , cellulitis , regimen , microbiology and biotechnology , antibiotics , gastroenterology , surgery , immunology , bacteria , biology , genetics , virus
The safety and efficacy of ceftazidime administered as 0.5 g every 8 hours (q8h) or 1.0 g q8h for at least 5 days were compared in 197 patients and found to be effective in the treatment of cellulitis. abscesses, skin ulcers, and wound infections. Staphylococcus aureus was the predominant pathogen in both treatment groups with approximately half of the isolates from each treatment group being gram‐positive. Pseudomonas aeruginosa was the most common gram‐negative isolate. P. aeruginosa, Proteus mirabilis, and Escherichia coli each comprised 5–12% of the isolates from each treatment group. Clinical cure or improvement was achieved in 98.7% of the patients in each treatment group. Concurrently with clinically successful treatment, a high rate of bacteriologic eradication without superinfection was achieved with the 0.5‐g regimen (84% of all isolates) and the 1.0‐g regimen (92%).